Compare Novartis AG (NVS) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Sirius XM Holdings Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Sirius XM Holdings Inc trades at $26.51 (market cap $8.87B). The key difference: Novartis AG is far larger — about 30.3× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (4.1%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Sirius XM Holdings Inc for 102 Days on average.
| NVS | SIRI | |
|---|---|---|
Market Cap | $268.57B | $8.87B |
Volume | 1,532,573 | 4,324,672 |
Sector | Health | Media |
52-Week High | $168.62 | $32.59 |
52-Week Low | $121.80 | $19.92 |
Typical Hold Time | 82 Days | 102 Days |
Enterprise Value | $309.89B | $18.16B |
Dividend Yield | 3.31% | 4.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Sirius XM Holdings (SIRI) trades at $26.33, up 1.46% on the day, with a neutral technical signal and mixed earnings history. The stock shows attractive valuation metrics with a P/E of 10.57 and P/B of 0.75, while profitability remains solid with a 10.23% net margin. Recent news highlights the company's YouTube partnership potential and strong cash flow growth, with institutional buying activity noted in September 2026.
The outlook is cautiously optimistic with a consensus price target of $34.43 suggesting 31% upside, though risks include competitive pressures in audio streaming and execution on new initiatives. The company's debt reduction and stable cash generation support the bullish analyst sentiment, but investors should weigh the recent earnings misses against growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
